About the Study: Which patient populations with non–small cell lung cancer (NSCLC) with a mutation in the epidermal growth factor receptor (EGFR) would benefit from a first-line treatment of an intensified combination therapy? In this randomized phase 3 study including 294 patients with advanced NSCLC and an EGFR mutation and concurrent TP53 mutations, first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared with osimertinib alone (34.0 months vs 15.6 months; hazard ratio for disease progression or death, 0.44). This study provides evidence for incorporating TP53-based molecular risk stratification into first-line clinical decision-making because the efficacy of intensified combination therapy justifies the added treatment-related burden in this high-risk population.
Osimertinib Alone or With Chemo in Advanced Lung Cancer
JAMA Network
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
